PFE Pfizer Inc.

Pfizer Declares Third-Quarter 2021 Dividend

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on Twitter at and and like us on Facebook at .

EN
24/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pfizer Inc.

 PRESS RELEASE

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Mult...

NEW YORK--(BUSINESS WIRE)-- . (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. “For healthcare teams treating patients with ...

 PRESS RELEASE

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting. Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at . On the day of t...

 PRESS RELEASE

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYS...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial () MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2. Among US adults 18...

Pfizer Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

Pfizer Invites Public to View and Listen to Webcast of May 1 Conferenc...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to regis...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch